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ABSTRACT
The human XPBC/ERCC-3 was cloned by virtue of its
ability to correct the excision repair defect of UV-
sensitive rodent mutants of complementation group 3.
The gene appeared to be in addition implicated in the
human, cancer prone repair disorder xeroderma
pigmentosum group B, which is also associated with
Cockayne's syndrome. Here we present the genomic
architecture of the gene and its expression. The
XPBC/ERCC-3 gene consists of at least 14 exons
spread over approximately 45 kb. Notably, the donor
splice site of the third exon contains a GC instead of
the canonical GT dinucleotide. The promoter region,
first exon and intron comprise a CpG island with several
putative GC boxes. The promoter was confined to a
region of 260 bp upstream of the presumed cap site
and acts bidirectionally. Like the promoter of another
excision repair gene, ERCC-1, it lacks classical
promoter elements such as CAAT and TATA boxes, but
it shares with ERCC-1 a hitherto unknown 12 nucleotide
sequence element, preceeding a polypyrimidine track.
Despite the presence of (AU)-rich elements in the
3'-untranslated region, which are thought to be
associated with short mRNA half-life actinomycin-D
experiments indicate that the mRNA is very stable
(t 1/2> 3h). Southern blot analysis revealed the
presence of XPBC/ERCC-3 cross-hybridizing fragments
elsewhere in the genome, which may belong to a
related gene.
INTRODUCTION
To cope with DNA lesions induced by physical and chemical
agents all living organisms have acquired a complex network of
DNA-repair pathways (see ref. 1 for a comprehensive review).
The best studied repair process is that of nucleotide-excision
repair. In contrast to E. coli (see for recent overviews: ref. 2-4)
little is known about the molecular mechanism of the nucleotide
GenBank accession no. M31899
excision repair pathway in eukaryotes. In mammals two classes
of excision repair-deficient mutants can be discerned: a minimum
of 8 complementation groups within the class of laboratory-
induced rodent mutant cells (5), and within the category of human
mutants at least 7 complementation groups in cells from excision-
deficient xeroderma pigmentosum (XP) patients (designated XP-A
to XP-G-the sole patient comprising group H falls into
complementation group D [6-9]) and three groups in the repair
disorder Cockayne's syndrome (CS) (see refs. 10 and 11 for
recent reviews). This extensive genetic heterogeneity suggests
a considerable biochemical complexity underlying the nucleotide
excision repair pathway. The impact of nucleotide excision repair
mechanisms at the level of the organism is illustrated by the
clinical manifestations of these syndromes. Both XP and CS are
rare, autosomal recessive disorders characterized by hyper-
sensitivity of the skin to UV exposure and frequently neurological
defects. XP patients, in addition, present abnormal pigmentation
and other skin defects in sun-exposed parts and a predisposition
to skin cancer (see 12 for an extensive review). CS patients, who
have only a subtle defect in excision repair (13) display skeletal
deformation and severe mental retardation but not a dramatic
increase in incidence of skin cancer. Efforts in several laboratories
to isolate XP-correcting genes by DNA-mediated gene transfer
(14,15) are hampered by the relatively poor transfection
properties of most SV40-immortalized human fibroblast lines
(16). Recently, Tanaka and co-workers described the cloning of
the XP-A correcting gene (XPA-C) after large scale transfection
experiments to an SV40-immortalized fibroblast line (17,18). In
contrast, considerable progress has been made in cloning human
DNA repair genes utilizing UV-sensitive Chinese hamster cells
as recipients for DNA-mediated gene transfer. The genes
correcting the rodent repair defects are termed Excision-Repair
Cross-complementing rodent repair deficiency or ERCC genes,
where the number refers to the rodent complementation group,
that is corrected by the human gene. In this way the human
ERCC-J, 2, 3, 5 and 6 genes have been isolated (19-23), as
well as the XRCC-J gene that corrects the X-ray sensitivity of
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CHO mutant EM-9 (24). The importance of the category of
rodent mutants as a model for human repair disorders is stressed
by our recent finding that a mutation in the ERCC-3 gene
underlies the inborn defect in XP complementation group B. This
group represents a very rare conjunction of XP as well as CS.
The XPB-correcting XPBC/ERCC-3 gene encodes a putative
DNA helicase (25). In this report we present the architecture of
the XPBC/ERCC-3 gene, its pattern of expression and studies
on its promoter.
MATERIALS AND METHODS
General procedures and Nucleic Acids
Purification of nucleic acids, restriction enzym digestions, gel
electrophoresis, nick translation and filter hybridization were
performed according to established procedures (26). The
fragments used for nick translation were: a 1.3-kb Pst I fragment
from pRGAPDH-13 (27), carrying a rat GAPDH cDNA; the
1.7-kb EcoRI-ClaI fragment from pHM-l (28) carrying exon 3
and 3' flanking sequences of the human c-myc gene. DNA
sequences were determined by the dideoxy-chain termination
method (32) with Sequenase (United States Biochemicals) or Taq-
Track (Promega), and with either M13-or sequence-specific
oligonucleotides as primers. Oligonucleotide primers were
synthesized in an Applied Biosystem DNA syntheziser.
Cell culture and transfection
The UV-sensitive CHO cell line 27-1 (29) and HeLa cells were
grown in DMEM/F10 (1:1) medium supplemented with 5%
newborn and 5 % fetal-calf serum and antibiotics. Human primary
fibroblasts (VH10) cells were cultured in the same medium
supplemented with 10% fetal-calf serum. For promoter studies
XPBC/ERCC-3 DNA constructs (2-5 itg) were cotransfected
with the dominant marker pSV3gptH (1-2 yg) to 27-1 cells as
described previously (21). After approximately two weeks of
selection in XGPT medium, cells were reseeded and UV-
irradiated with 12 J/m2 (254 nm peak, at a fluence rate of 0.5
J/m2); the surviving clones were fixed and counted. Transient
transfection experiments were carried out using HeLa TK- cells
as recipients and (10 4g) CAT plasmids as described before (30).
CAT activity was assayed as detailed earlier (31).
UV-induction
HeLa cells were grown to near-confluency and after rinsing with
PBS (phosphate-buffered saline), UV-irradiated (254 nm peak)
and subsequently incubated with culture medium for various
periods of time, after which they were harvested and used for
poly (A)+ RNA isolation (26).
Determination of mRNA stability
To determine the stability of XPBC/ERCC-3 mRNA,
actinomycin-D was added to exponentially growing cultures of
HeLa TK- cells to a concentration of 5 tg/ml. At several time
points after addition of actinomycin-D cells were harvested and
total cellular RNA isolated.
XPBC/ERCC-3 promoter constructs
The genomic 4.2-kb PstI fragment of cosl containing
XPBC/ERCC-3 5' sequences, was subcloned into pTZ18 yielding
pHEP (see Fig. 2 for relevant restriction sites of the
XPBC/ERCC-3 5') region. The XPBC/ERCC-3 cDNA clone
pCD 1 has been described previously (21). From pHEP, various
XPBC/ERCC-3 5' segments were isolated, using restriction sites
indicated in Fig. 5A and cloned in front of the XPBC/ERCC-3
cDNA. This yielded the minigene constructs pHEP-1 (containing
the approximately 1 kb HindJIIISstII fragment) and pHEP-3
(containing the 378 bp NcoI fragment of which the ATG start
codon was removed by Mung-Bean exonuclease). This was
confirmed by sequence analysis. Similarly constructs were made
in which the XPBC/ERCC-3 cDNA was replaced with the CAT
gene derived from vector pBA-CAT (33). These pHEP-CAT
constructs are indicated in Fig. SA.
RESULTS
Architecture of the XPBC/ERCC-3 gene
Cosmids cosl, cos2 and cos8, harbouring the major part of the
human XPBC/ERCC-3 gene were isolated from a cosmid library
originating from a repair-proficient secondary transformant of
CHO mutant 27-1. Transfection of the three cosmid clones
separately or together to 27-1 cells did not result in the generation
of UV-resistant transformants, in contrast to cDNA clones.
Detailed physical maps were prepared for the cloned human
inserts of the cosmids (21, Fig. lA). Comparison of
chromosomal DNA from the secondary transformants and HeLa
cells with the cloned cosmid inserts revealed that the human insert
of cos8 differed in one area not covered by cos 1 and 2 from
the DNA in the secondary transformant from which the cosmid
library was derived and from HeLa DNA. This rearrangement
affected a region that was 'coinherited' by all independent
transformants, analyzed and therefore likely belonged to the
XPBC/ERCC-3 gene (21 and data not shown). The absence of
this segment provides a reasonable explanation for the consistent
inability of the cosmids to correct the repair defect of 27-1 cells.
The size of the gene and its location on cosl, cos2 and cos8
was determined in several ways: i. by systematic comparison of
specific parts of the cloned XPBC/ERCC-3 region with the DNA
of independent genomic 27-1 transformants using Southern blot
analysis ii. By hybridization of different probes of a full-length
XPBC/ERCC-3 cDNA to the inserts of cos 1 and cos 8. From
these results we deduced that the XPBC/ERCC-3 gene covers
a region of circa 45 kb. of which a segment of approximately
9 kb. constituting the 3' end of the XPBC/ERCC-3 gene, is not
present in the insert of cos8 due to a rearrangement. A detailed
physical map of the XPBC/ERCC-3 region on cos 1, cos2 and
cos8 is presented in Fig. 1A. The borders of the gene and the
positions of the exons were determined and the intron-exon
junctions sequenced. The first intron/exon has an extremely high
C+G content (80%; data not shown) and appears to constitute
part of a CpG-rich island. A clustering of sites for the restriction
enzymes BssHII, SstII, SmaI, NaeI and NarI with one or more
CpG dinucleotides in their recognition sites characteristic for CpG
islands (35) occurs in this area, as shown in Fig. 2. The sequence
between 70 to 90 bp upstream of the translation start site has
the potential to form a stem-loop structure with a calculated AG
of - 15.4 kcal/mol based on estimates of RNA secondary
structure stability (36) (see Fig. 3).
As shown in Fig. 3 and 4A, all sequences around the intron-
exon borders are consistent with the consensus donor and acceptor
splicing signals (37), with the notable exception of the 5' splice-
donor site of the third intron where instead of the customary GT
a GC dinucleotide is observed. Identical sequence data were
obtained from two independently isolated genomic cosmid clones,
ruling out the possibility of a cloning artifact. Potential branch-
Nucleic Acids Research, Vol. 19, No. 22 6303
A 10 20 30 40
l~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~~~~~~~~~m
. Sall
KpnlI
Xhol
Sacil
Nae
Xbal
Pst
Ba
I~~ ~I I III
Ec
r~~~~~~~~~~-~~ ~~ ~~ ~~~~~~~~~~~~~~~----------------
B
P ~ ~ ~
~~~~
P P P P P P P H P| n3
II IV11 VV II Vl Vll oX X Xi Xll Xill ^lV
amHI
ind ill
maI
co RI
Fig. 1. Genomic organization of the XPBC/ERCC-3 gene. A. Detailed physical map. The arrowhead (below the kb scale) refers to the genomic region that is not
present in cos8 and hitherto refractory to cloning (21). The presence of additional small exon-containing fragments in the missing area is not excluded. Small arrows
(top) define the regions for which not all restriction-enzyme cleavage sites have been mapped. Restriction fragments smaller than 1 kb are not indicated except for
the 5' region of the XPBC-ERCC-3 gene. B. Intron-exon structure. Exons (filled boxes) are indicated with Roman numbers. The exon or exons in the region of
which the corresponding genomic part not has been cloned can not be precisely mapped and are depicted with an open box. The distance from exon XIII to exon
XIV is fixed, however, the exact location within the 3' PstI fragment is not known. The dot denotes the polyadenylation signal AATAAA. Abbreviations: P: PstI
and H: HindI
sites are present at 30-50 bp upstream of the splice-acceptor
sites (Fig. 4A). The deduced transcriptional orientation and the
genomic organization are depicted in Fig. lB. The cloned
genomic DNA from cosl, cos2, and cos8 appeared to harbor
exons 1 to 12 (corresponding to position 2040 in the cDNA).
In order to isolate parts of the remaining 3' region that was sofar
refractory to cloning, we amplified the 3' part of the HeLa
XPBC/ERCC-3 gene by means of the polymerase-chain reaction
(PCR) using cDNA-derived oligonucleotide primers covering the
cDNA sequence between positions 2158 and 2750. The
amplification resulted in a fragment of approximately 2.1 kb,
containing the last exon and 153 bp from the preceding one. Using
amplimers based on more 5' cDNA sequences that where absent
in cos8, we did not succeed in amplifiying the missing genomic
fragment. This may be explained by the presence of a large intron
in the region between the oligonucleotide primers used. From
the location of the known exons and their borders it can be
deduced that there must be at least one exon between nucleotide
2040 and 2158 which is missing in our genomic clones.
Therefore, the human XPBC/ERCC-3 gene consists of a
minimum of 14 exons ranging in size from 50 to 439 bp spread
over a region of approximately 45 kb (Fig. IA). At the 3' end
of the gene a 309-bp non-coding region (including the stop codon
TGA) contains the polyadenylation signal AATAAA (38) which
is situated 28 bp 5' to the poly (A) addition site (Fig. 3). At
positions 2694 and 2705 two AUUUA motifs are located which
in other genes have been implicated in determining mRNA
stability (see below) (39).
The XPBC/ERCC-3 promoter
The nucleotide sequence of the region upstream of the first exon
is shown in Fig. 3. To determine the position of the start site
of the mRNA SI analysis and primer-extension was attempted,
but did not reveal a major cap site, probably due to the high GC-
content of the entire region (70%). However, transfection of
cDNA expression plasmids into human cells revealed a transcript
Si Nc S Sm
H Nc N -L( BNo
I;I ~~~~~~~IfII
I ~~~~~~~~II
100 bp
Fig. 2. Fine map of the 5' end of the XPBC/ERCC-3 gene. Exons I and II are
indicated by boxes. The non-coding region is denoted by an open box, the coding
sequence by a hatched boxes. The genomic fragments HindI/SacH (site Sl);
HindII/NarI and NcoI/NcoI were used for the minigene constructs and the
promoter CAT plasmids as described in Materials and Methods. Abbreviations:
B: BssHH]; H: HindI; Hp: HpaII; Ne: NaeI (2 sites close together); N: NarI;
Nc: NcoI; S: Sacd; Sm: SnaI.
of the same size as the endogenous XPBC/ERCC-3 mRNA,
indicating that the cDNA must be (nearly) full-length (data not
shown). Moreover, 17 and 19 nucleotides upstream of the start
of the longest cDNA clone pCDI, two putative cap sites were
found matching with the loosely defined consensus for
transcription initiation PyPyCAPyPyPy (starting on the A residue)
(Fig.3; 40). A comparison of the human 5' XPBC/ERCC-3
genomic sequence with the corresponding mouse sequence
indicated a long stretch of homologous nucleotides around this
region (Weeda et al. unpublished results). Therefore, we think
that this conserved segment is a likely candidate for representing
the transcription initiation site, however, further experiments are
required to prove this presumption. The 5' upstream region lacks
the canonical TATA and CAAT promoter signals but harbors
a reverse sequence motif matching the consensus SPl-binding
site (G/T)GGGCGG(G/A)(G/A)(C/T) (41) at positions-89
to-81 (indicated in Fig. 3 with 'GC'). A noteworthy feature of
the 5' flanking region is the presence of a pyrimidine-rich stretch
at position -243/-225 (Fig. 3, dotted line, Fig. 4B). Upstream
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ccatggactcaggtctcattctctctctctctctctcVcacacacatttattgcccacatggcttcattaaaatttaagttccagaaggatgaggcctttaattcgcgcactacacaggt
..........................
Nc *gc
gctcaacacacagtattttccttcagttgtagagaaB tgaacagtggatgBcccccgccg5tgggtcgcacgagctatcagatcgggggtcgctggctctccgctcttccagccacccac
atcacggcgcctagaggcgggaca tcctgtgtggacaaca+gggagctLtccggattgagccggaa*gtccccccagagcgga tgccgcggcgggcc tgtggg'agcggggtc tcttctctct
N6H.N G K R D R A D R D K K K S R E R H Y E D E E
gctcttgDtagctgccATGGGCAAAAGAGACCGAGCGGACCGCGgtgtcgcgtgag - - .4kb- -ggtatcttgcED gACAAGAAGAAATCCAGGAAGCGGCACTATGAGGATGAAGA
* c
D D E E D A P G N D P O E A V P S A A G K O V D E B G T K V D E Y G A K D Y R L
GGATGATGAAGAGGACGCCC CGGGGAACGACCCTCAGGAAGCGGTTCCCTCGGCGGCGGGGAAGCAG6GTGGATGACTCAGGCACCAAAGTGGATGAATATGGAGCCAAGGACTACAGGCT
R P L K D D H T 9 R P L W V A P D G H I F L E A F S
GCAAATGCCCCTGAAGGACGACCACACCTCCAGGCCCCCTCTGGGTGgtacatgccc- ----6.1kb ----- ggtatctctcaGCTCCCGATGGCCATATCTTCTT6GAAGCCTTCTC
P V Y K Y A G D F L V A I A E P V C R P T H V H E Y K L T A Y S L Y A A V S V G
TCCAGTTTACAAATATGCCCAAGACTTCTTGGTGGCTATTGCAGAGCCAGTGTGCCGACCAACCCATGTGCATGAGTACAAACTAACTGCCTACTCCTTGTATGCAGCTGTCAGCGTTGG
L B T S D I T E Y L R K L S K T G V P D G I M F I K
GCTGCAAACCAGTGACATCACCGAGTACCTCAGGAAGCTCAGCAAGACTGGAGTCCCTGATGGAATTATGCAGTTTATTAAGgcaag9tga*ca*gc -- - -- 2.9kb -- - -- c tgtatttgca
L C T V S Y G K V K L V L K H N R Y F V E S C H P D
gTTGTGTACTGTCAGCTATGGAAAAGTCAAGCTGGTCTTGIAAGCACAACAGgtaagattccat ----- 0.35kb-----ccctacttgc*gATACTTCGTTGAAAGTTGCCACCCTGATG
V I D H L L V D P V I R E C R L R N S E G E A T E L I T E T F T S E S A
TAATCCAGCATCTTCTCCAGGACCCCGTGATCCGAGAATGCCGCTTAAGAAACTCTGAAGGGGAGGCCACTGAGCTCATCACAGAGACTTTCACAAG CAAATCTGCCgtatgtgga*ctc -
I S T A E SS G G P S T S R V T D PF G K S D I P M D L F D
- - -
-0.2kb- -- -- cctctc tcacagATTTCTAAGACTGCTGAAAGCAGT6GGTGGGCCCTCCACTTCCCGAGTGACAGATCCACAGGG TAAATCTGACATCCCCATGGACCTGTTTGACT
F Y E B M D K D E E E E E K T V T V S F E V K B E M I
TCTATGAGCAAATGGACAAGGATGAAGAAGAAGAAGAAGAGACACAGACAG TGTCTTTTGAAGTCAAGCAGSttagtgaa*tcgV- V.4 5kb-----ccctctttccagGAAATGATT
E E L B K R C I H L E Y P L L A E Y D F R N D S V N P D I N I D L K P T A V L R
GAGGAACTCCAGAAACG TT6GCATCCACCTGGAGTACCCTCTGTTGGCAGAATATGACTTCCGGAATGATTCTCGTCAACCCTGATATCAACATTGACCTAAAGCCCACAGCTGTCCTCAGA
P YD E K S L R K M F G N G R A R S G V I V L P C G A
CCCTATCAGGAGAAGAGCTTGCGAAAGATGTTTGGAAACGGGCGTGCACGTTCGGGGGTCATTGTTCTTCCCTGCGtagtgtacaga - - - - V-1 8kb--- ttttttcctcagGTGCT
G K S L V G V T A A C T V R E R C L V L G N S A V S V E D WR A D F K Rw B T I
GGAAAGTCCCTGGTTGGTGTGACTGCTGCATGCACTGTCAGAAAACGCTGTCTGGTGCTGGAGCAACTCAGCTGTTTCTGTGGAGCAGTCGAAAGCCCAGTTCAAGATGTGGTCCACCATT
D D S DI C R F T S D A K D K P I G C S V A I S T Y M L A H T T K R S W E A E
GACGACAGCCAGATCTGCCGGTTCACCTCCGATGCCAAGGACAAGCCCATCGGCTGCTCCGTTGCCATTAGCACCTACTCCATGCTGGGCCACACCACCAAAAGGTCCTGGGAG GCCGAG
R V M E W L K T V E W G L M I L D E V H T I P A K
H F
CGAGTCATGGAGTGGCTCAAGACCCAGGAGTGGGGCCTCATGATCCTGGATGAAGTGCACACCATACCAGg tagcaggctg--5- Skb ----- tgtttctggtagCCAAGATGTTC
R R V L T I V B A H C K L G L T A T L V R E D D K I V D L N F L I G P K L Y E A
CGAAGGGTGCTCACCATCGTGCAGGCCCACTGTAAGCTGGGTTTGACTGCGACCCTCGTCCGCGAAGATGACAAAATT6 TGGATTTAAATTTTCTGATTGGGCCTAAGCTCTACGAAGCC
N W M E L B N N G Y I A K V D C A E V W C P M S P E F Y R
AACTGGATGGAGCTGCAGAATAATGGCTACATCGCCAAAGTCCAGTGTGCTGAGgAtaBgctgggcct-V--- 3b--- attacAgGTCTGGTGCCCTATGTCTCCTGAATTTTACCG
E Y V A I K T K K R I L L Y T M N P N K F R A C B F L I K F H E R R N D K I IG
GGAATATGTGGCAATCAAAACCAAGAAACGAATCTTGCTGTACACCATGAACCCCAACAAATTTAGAGCTTGCCAGTTTCTGATCAAGTTTCATG AAAGGAGGAATGACAAGATTATTGT
F A D N V F A L K E Y A I R L N K P Y I Y G P T S D G
CTTTGCTGACAATGTGTTTGCCCTAAAGGAATATGCCATTCGACTGAACAAgta*agattga- ----6.5kb----- *ttcttctctgACVCCTATATCTACGGACCTACGTCTCAGGG
E R M DI L B N F K H N P K I N T I F I S K V G D
T S
GGAAAGGATGCAAAT TTCTCCAAATTTCAAACCCCAAAATTAACACCATCTTCATATCCAAgtttgtgtggca* - - -- -14k-b----- ttgtttctgtagGTAGGTGACACTTC
F D L P E A N V L I Q I S S H G G S R R B E A D R L G R V L R A K K
GTTTGATCTGCCGGAkAGCAAATGTCCTCATTCAGATCTCATCCCATG GTGGCTCCAGGCGTCAGGAAGCCCAA,AGGCTAGGG6C6GGGTGCTTCCAGCTAAAAAAGg taaa*gtggcct- -- -
G M V A E E Y N A F F Y S L V S D D T B E M A Y S T K R D R F L V D V G Y
- > 10kb -- - --GGATGGTTGCAGAAGAGTACAATGCCTTTTTCTACTCACTGGTATCCCA6GGACACACAGGAAATGG CTTACTCAACCAAG CGGCAGAGAT.CTTGGTAGATCAAGGTTA
S F K V I T K L A G M EE E D L A F S T K E E D BO L L B K V L A A T D L D A E
TAGCTTCAAGGTGATCACGAAACTCGCTGGCATGGAGGAGGAAGACTTGGCGTTTTCGACAAAAGAAGAG CAACAGCAGCTCTTACAGAAAGTCCTGGCAGCCACTGACCTGGAT6GCCGA
E E V V A G E F G DR S BO A s R R F G T M S BM S G
GGAGGAGGTGGTGGCTGGGGAATTTGGCTCCAGATCCAGCCAGgtggtaaatgg - ---- 1.6kb ----- ccttcccggcagGCATCTCGGCGCTTTGGCACCATGAGTTCTATGTCTGG
A D D T V Y M E Y H R S K A P S FH V H P L F K R F R K
GGCCGACGACACTGTGTACATGGAGTACCACTCATCGCGGAGCAAGGCGCCCAGCAAACATGTACACCCGCTCTTCAAGCGCTTTAGGAAATGAtgActtaggcagggactcgttc*
accggcgcVttggcaccVttgttggaaagggatttt ttcctVBctBtttttcttcctcVBVVVttt ctV ctccagcg ttggccaaa ttgtgctgaggaagaVtgcatcaagggcttggc
tgtgccttcataggtcatctagggttttataaagagBgaggagacaaVtattttttcaaactttttggggagtggggtcatttctgtatataaaaaatgttaa*tatttaaggtgtatttat
3'
gttaccgttctgaataaacagVatggaccattctSBBVVStVVtcattgtacaaStgcttttt
Fig. 3. Nucleotide sequence of the 14 exons in the XPBC/ERCC-3 gene including intron-exon junctions, and 5' and 3' flanking genomic sequences. Coding sequences
are depicted in upper case. The deduced amino acid sequence is indicated above the nucleotide sequence in one-letter code. A pyriminide-rich stretch in the 5' region
is indicated by a dotted line, the putative transcriptional start sites by open triangles. The vertical arrow in the 5' region denotes the start of the longest cDNA clone.
The NcoI (Nc) and NarI (Na) restriction-sites used for promoter constructs are indicated. The G/C-rich box (potential SP-l binding site) is indicated by (GC) and
single underlining, the inverted repeat is indicated by two large arrows, the (AU)-rich sequences and polyadenylation signal are underlined. The CAYTG region
is indicated by double underlining. The vertical arrow in the 3' region below the sequence indicates the polyadenylation site as determined by sequence analysis.
3' XPBC/ERCC-3 flanking sequences are determined from DNA clones obtained by inverted PCR. The region between the arrowheads has not been cloned at the
level of the genome and may contain extra introns.
of this polypyrimidine stretch a sequence motif: CTCAGGT/CC-
ACA (-255 to -244) (Box I) is located, which is also present
in front of a polypyrimidine stretch in the 5' region of the ERCC-J
gene (42) (see fig. 4B). The conservation of this region suggests
that it has a function in regulation of transcription of both genes.
We have searched in the EMBL sequence data base for nucleotide
sequences homologous to this region, but to no avail.
To verify whether the XPBC/ERCC-3 5' flanking sequences
can drive transcription, several constructs were made by inserting
XPBC/ERCC-3 5' fragments in front of the chloramphenicol
acetyltransferase gene (CAT) of vector pBACAT (see Materials
and Methods for details and Fig. 5A). The resulting constructs
were tested for transient expression by transfection into HeLa
TK- cells and assay for CAT activity 48h after transfection. As
shown in Fig. SB two constructs, pHEP-catl and pHEP-cat3
induced approximately the same CAT activity. A deletion clone
(pHEP-cat5) ending at position -14 did not show any CAT
activity, which is in agreement with our tentative assignment of
the cap site. The findings imply that the region 259 bp upstream
of the putative cap site harbours promoter activity. As a negative
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Fig. 5. Promoter activity of 5' XPBC/ERCC-3 flanking sequences. A. The
transfected promoter-CAT constructs are shown schematically. CAT activity is
indicated by + or -. 1 :pHEP-catl; 2:pHEP-cat2; 3:pHEP-cat3; 4:pHEP-cat4;
5:pHEP-cat5; 6:pHEP-cat6. Abbreviations: H: HindIII; Na: Narl; N: NcoI; S:
SstII. B. Analysis of the human XPBC/ERCC-3 promoter in HeLa TK- cells.
CAT-expression plasmids containing the various promoter fragments were
transfected into HeLa Tk- cells. After normalization of the protein content CAT
activity was measured. The ug promoter CAT plasmid was used for each
transfection. For the RSVCAT control (lane c: pRSVCAT) half of the lysate was
used. Numbering corresponds with Fig. 4A.
AGCCAGIGTG AGTAAATGG (1.6)
3' POLY A TAIL
PY- rich -220
XPBC/ERCC3 5' AATTCTTCCTTACCCATGG CTCAGGTCACA*CTCTCTCTCTCTCTCTCACACACAC 3'
** ** C***3***** * * * *
EXCC1 5' AAATTGACAAXCCGCAA TTTCTCAGCCGGT 3 '
-120 -100 -80
Fig. 4. A. Structural organization of the XPBC/ERCC-3 gene. The nucleotide
sequence of each intron-exon junction is shown. Vertical lines represent intron-
exon borders, Splice acceptor and donor sequences are all except one in accordance
with the reported consensus sequence (Y)nNCAG/GT and AAG/GTA
respectively (40). The third splice donor site harbouring an unusual GC dinucleotide
is boxed. Exon numbering is as in Fig. lB. The size of each intron and exon
(in kb and bp, respectively) is given between brackets. Potential branch sequences
matching the loosely defined (YNYTRAR) consensus, if present are underlined.
B. Alignment of a part of the 5' human XPBC/ERCC-3 and ERCC-J regions
(42). The homopurine-homopyrimidine tract (Py) and the homologous region (box
I) are indicated. Nucleotide numbering is based on the (putative) transcriptional
start sites of both genes.
control, the promoter fragments of pHEB-catI, -3 and -5 in
the inverted orientation (yielding pHEP-cat2, -4 and -6
respectively) were transfected into HeLa TK- cells.
Surprisingly, pHEP-cat2 induced also clear CAT activity
(Fig. 4A, lane 3). This suggests that the 376-bp NcoI fragment
also includes a promoter and cap site in the reverse direction.
Further proof that the promoter of the XPBC/ERCC-3 gene
is located between the presumed cap site and -259 was obtained
using plasmids containing genomic fragments in front of the
XPBC/ERCC-3 cDNA (see Materials and Methods) and co-
transfection of these constructs to the UV-sensitive 27-1 hamster
cells with the dominant selection marker plasmid pSV3gptH.
Transformants were selected with mycophenolic acid for
expression of the co-transfected E. coli gpt gene and with UV
light for XPBC/ERCC-3 expression. The results summarized in
Table I show that pCDl, harboring XPBC/ERCC-3 cDNA under
the direction of the strong SV40 early promoter yielded a
comparable number of UV-resistant clones as XPBC/ERCC-3
constructs driven by the endogenous promoter.
Table I.
Transfected DNA fraction of transformant
surviving UV-dose*
pcDl cDNA + SV40 early promoter 31
pcDl-SV cDNA without promoter 0.5
pHEP-1 cDNA + 1.1 kb promoter fragment 20
pHEP-3 cDNA + 0.4 kb promoter fragment 20
*average of 5 dishes (ca. 100-200 colonies per dish)
Identification of the XPBC/ERCC-3 promoter region. XPBC/ERCC-3 promoter
activity was determined by counting the number of UV-resistant clones after co-
transfection of XPBC/ERCC-3 minigene constructs and the dominant marker
pSV3gptH into 27-1 cells, reseeding the colonies and irradiation with 12 J/m2.
The relative survival value (%) was determined by dividing the number of colonies
in UV-irradiated dishes by the corresponding number of unirradiated dishes.
Regulation of XPBC/ERCC-3 gene expression
Northern blot analysis of various human cell lines revealed a low
level of XPBC/ERCC-3 transcription (21, and unpublished
results). To investigate whether the XPBC/ERCC-3 promoter is
induced by DNA-damaging agents, Northern blot analysis was
performed on poly(A)+ RNA of HeLa cells at several time
points after UV-irradiation (1 J/m2). Hybridization with the
probe for the -y-actin gene indicated that approximately equal
amounts of poly (A)+ RNA were loaded in each lane. As an
internal control for UV-induction, the filter was rehybridized with
a metallothionein Ha (MTIIa) cDNA probe. It has been reported
that MTIIa expression is strongly induced by UV light and the
phorbol ester, TPA treatment (43). From Fig. 6 it is evident that
UV irradiation with a UV dose of 1 J/m2 (or 10 J/m2; data not
shown) did not result in significant changes of XPBC/ERCC-3
transcription during a period of 12 h. Although HeLa cells are
of epidermal origin, they are transformed and may have lost a
UV-inducible response present in vivo. Therefore, we have also
analyzed the effect of UV-irradiation on ERCC-3 expression in
short term cultured skin keratinocytes. However, also in this case
no significant UV-induction was observed (data not shown).
To examine whether expression of XPBC/ERCC-3 fluctuates
with the proliferative state and/or with the stage in the cell-cycle,
primary human diploid fibroblasts were synchronized by growth
arrest at high cell density and stimulated to proliferation by
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Fig. 6. Effect of UV irradiation on XPBC/ERCC-3 transcription. Poly(A)+ RNA
(approximately 7.5 sg) of exponentially growing UV-irradiated (1 J/m2) HeLa
cells was size-fractionated on a 1% agarose gel and after blotting to nitrocellulose
hybridized to a 32P-labeled, nick-translated XPBC/ERCC-3 cDNA probe, a 'y-
actin cDNA probe and to a metallotionein IA cDNA probe.
Fig. 7. Effect of acfinomycin-D treatment of the XPBC/ERCC-3 mRNA stability.
Total cytoplasmic RNA (50 1tg) was isolated at the time points indicated from
HeLa cells which were grown in the presence of 5 jg/ml actinomycin-D. After
size fractionation of equal amounts of RNA, the RNA was blotted onto
nitrocellulose filters. The filter was hybridized with an XPBC/ERCC-3 cDNA
probe. The same filter was rehybridized with a human c-myc genomic probe and
GAPDH cDNA probe.
reseeding in medium containing 15% fetal-calf serum. Northern
blot analysis showed that the XPBC/ERCC-3 transcription levels
are constant and not significantly induced during the S-phase and
M-phase (data not shown).
An additional region of interest is the 3'-UTR region of the
gene. 3' untranslated sequences of several transiently expressed
genes have been implicated in mRNA stability. Particularly an
(AU)-rich region with the core sequence AUUUA was found to
induce mRNA lability (39). Such elements are present in the 3'
untranslated region of the XPBC/ERCC-3 sequence shown in
Fig. 3. This prompted us to investigate the stability of cytoplasmic
XPBC/ERCC-3 mRNA. To that end actinomycin-D was added
to HeLa TK- cells, and cytoplasmic RNA was isolated after
several time intervals to determine the half-life ofXPBC/ERCC-3
mRNA. Northern blot analysis (Fig. 7) shows that even after
3 h of treatment with actinomycin-D no significant differences
in XPBC/ERCC-3 mRNA amounts could be detected. As a
Fig. 8. Southern blot analysis of XPBC/ERCC-3 genomic seqeunces. High-
molecular weight DNA (15 Fg) from HeLa cells and a secondary repair-proficient
transformant (STI -1) was digested with PstI and size-fractionated on a 0.8%
agarose gel. The DNA was blotted and hybridized with a 375 bp 3' XPBC/ERCC-3
cDNA probe harboring a part of the last exon. The cross-hybridizing genomic
restriction fragment is indicated with an triangle.
positive control on the effect of actinomycin-D, the same filter
was also hybridized with a human c-myc probe, which has been
reported to have a short half-life of 15-30 min (39). A decrease
in the relative amount of c-myc mRNA was readily observed on
the same filter. The addition of inhibitors of protein synthesis
like cycloheximide did not influence the XPBC/ERCC-3 mRNA
stability (data not shown).
Cross-hybridising genomic sequence outside the XPBC/
ERCC-3 locus
Southern blot hybridization of human genomic DNA with
XPBC/ERCC-3 cDNA produces a complex pattern of hybridizing
bands. Systematic comparison by Southern blot analysis revealed
that in Hela genomic DNA extra fragments hybridized that can
not be accounted for by the map and are absent in DNA of repair
proficient transformant ST1-1 with an intact copy of the gene.
An example using a 3' XPBC/ERCC-3 cDNA probe is shown
in Fig. 8. This 375 bp probe hybridizes to a 3.7 kb genomic PstI
fragment. The hybridization pattern of genomic DNA from HeLa
cells revealed the presence of an additional restriction fragment
of approximately 2.1 kb not present in DNA of ST1-1 nor in
DNA of other secondary UV-resistant 27-1 transformants. Similar
results were obtained using 5' XPBC/ERCC-3 cDNA probes.
Hybridization to other human DNA's (the human lymphoblastoid
cell line; GM1855), gave identical results (data not shown),
indicating that this finding can not be explained by fragment
length polymorphisms. We concluded that a cross-hybridizing
sequence exists elsewhere in the human genome.
DISCUSSION
In this paper the physical organization and expression of the
human XPBC/ERCC-3 is presented. The gene is approximately
45 kb long and consists of at least 14 exons. Virtually all 5' and
3' splice boundaries in functional genes obey the GT-AG rule
(37). The importance of the conserved GT dinucleotide in the
splice donor sequence has been examined in naturally occurring
mutations (44-46) and after site-specific mutagenesis of GT to
GG in 5' splice sites of an intron in adenovirus or in the rabbit
4::.
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,B-globin (47-48). These studies showed that the presence of the
GT dinucleotide is a prerequisite for efficient RNA splicing.
However, a few active splice sites violating the GT-dinucleotide
rule have been found (49-52). In these rare instances a GC was
present instead of a GT. In our case, the XPBC/ERCC-3 gene
has been cloned from a UV-resistant 27-1 genomic transformant
which originally received and since then retained only 1 copy
of the (active) gene per cell. Therefore, we conclude that this
-GC- splice donor must be functional in vivo.
Functional domains of proteins are in many cases encoded by
discrete exons (53 -55). In this respect it is worth noting that
exon 2 of the XPBC/ERCC-3 gene codes for the postulated
nuclear location signal, whereas the presumed DNA-binding
domain is part of exon 3. The 7 motifs with striking homology
to conserved helicase domains are encoded by separate exons,
except for domains I and V.
Using a functional assay we have shown that the
XPBC/ERCC-3 promoter is located within a stretch of 259
nucleotides proximal to the putative transcription start site. The
XPBC/ERCC-3 promoter lacks the classical TATA and CAAT
boxes which are typically located in front of many eukaryotic
genes between positions -30 to -20 and -80, respectively (40).
However most 'housekeeping' genes are driven by promoters
that lack such elements but instead contain multiple GC boxes
(56-59). These GC boxes have the potential to bind transcription
factor SP1 (60). It has been shown that SPI can bind
asymmetrically to an SPI box (61) and can promote bidirectional
transcription (62-63). The presence of this SPI recognition
sequence in the XPBC/ERCC-3 promoter could account for the
bidirectional functioning of this DNA segment. The presence of
a cluster ofCpG dinucleotides was used as an indicator of a CpG-
rich island. It is now well established that CpG islands are often
found associated with promoter regions of genes and that nuclear
factors specifically bind to these sequences (64, 65).
Comparison of the sequence of the human XPBC/ERCC-3
promoter with that of ERCC-J revealed a homologous segment
consisting of two domains, a pyrimidine rich region preceeded
by a 12 nucleotide sequence (Fig. 4B). Regions with alternating
CT residues can adopt triple-helical structures in vitro (66) and
have been reported for promoters of constitutive or inducible
genes (67). Recently, footprint analysis has shown that in the
Drosophila heat-shock genes hsp70 and hsp20 such a pyrimidine-
rich region binds a transacting factor (68) which appears to be
similar or closely related to the described 'GAGA' transcription
factor (69). In addition, upstream of this pyrimidine-rich region
a motif is found that is highly similar to a stretch in the ERCC-J
promoter (box I). The possible involvement of these elements
in the basal transcription levels of ERCC-J and XPBC/ERCC-3
is currently under investigation.
Northern blot analysis of poly(A)+RNA from different cell
lines indicates low levels of XPBC/ERCC-3 transcripts. Low
constitutive or basal expression of repair proteins has also been
observed in E. coli and yeast (70). In bacteria efficient removal
of DNA lesions is carried out by an excision repair system that
is part of the DNA damage-inducible SOS response. In yeast,
agents that elicit this response induce the excision repair gene
RAD2 whereas transcription of RA4D, RAD3 and RAD10 is not
substantially affected by DNA damage (71). In addition, other
DNA damage inducible genes have been described (72 and
references therein), including DNA polymerase-,3 (73), DNA
ligase (74). XPBC/ERCC-3 expression does not seem to be
significantly induced by UV-light in HeLa cells and keratinocytes,
although we cannot exclude a 2-3 fold induction which is
difficult to detect in Northern blot analysis.
In both E. coli and Drosophila evidence is found for a partial
overlap between the cellular responses to heat-shock and DNA
damaging agents (75-77). Therefore we analysed XPBC/
ERCC-3 transcription also after heat-shock induction in HeLa
cells. Although Hsp7O transcripts were clearly induced, the
cellular level of XPBC/ERCC-3 transcripts was unaffected
(unpublished results).
At positions 2694 and 2705 in the 3' UTR of the
XPBC/ERCC-3 cDNA, (AU)-rich regions are found similar to
those described in 3' untranslated regions of several oncogenes
and transiently expressed genes. These regions are thought to
be involved in determining mRNA stability (78). The mRNA
for c-Fos seems to be more stable in constructs lacking this signal
(79) whereas the addition of this short sequence destabilized
previously stable messengers (80). The destabilizing effect of
(AU)-rich sequences could be due to interaction with the poly(A)-
protein complex (81). Recently, it has been shown that a trans-
acting factor can bind to this AUUUA motif (82). However,
based on our actinomycin-D experiments we conclude that
XPBC/ERCC-3 mRNA is not subject to this type of post-
transcriptional regulation, notwithstanding the occurrence of
similar sequence elements.
The organization of the human XPBC/ERCC-3 gene has been
elucidated. Remarkably, at least one additional genomic PstI
fragment cross-hybridizes to XPBC/ERCC-3 cDNA sequences
which is absent in DNA of secondary UV-resistant transformants
of 27-1 cells and hence, is not part of the XPBC/ERCC-3 gene.
Northern blots hybridized to different XPBC/ERCC-3 cDNA
probes show no cross-hybridization to other mRNAs, however,
we cannot exclude the existence of a very low-expressed mRNA.
This could implicate the presence of either a pseudogene or a
gene with sequence homology. Further experiments are underway
to discriminate between these two possibilities.
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